Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
NEW YORK--(BUSINESS WIRE)--Precision Biologics is pleased to announce the addition of Johns Hopkins Hospital as a collaborator on its ongoing Phase 2a clinical trial with its lead therapeutic compound NPC-1C (NEO-102). NPC-1C was highlighted on the cover of the June edition (Volume 62-issue 6) of the journal “Cancer Immunology, Immunotherapy (Springer)” and provides a detailed and in depth description of the discovery and development of this novel compound (see link below). In addition, encouraging clinical results of more than doubling of survival rates of pancreatic cancer and prolongation of survival of colorectal cancer patients were presented at the 2013 ASCO Annual meeting.
Help employers find you! Check out all the jobs and post your resume.
